Abbott Laboratories director Daniel J. Starks bought 10,000 shares on the open market on April 27, 2026, paying $92.65 per share for a total of about $926,540. An open-market purchase of this size is notable because it represents a personal cash outlay, rather than shares received through compensation programs or other no-cash transactions. Starks is a board director, meaning he helps oversee management and strategy but is not typically involved in day-to-day operations. Director buying can matter to investors because it reflects the decision of an insider with access to detailed reporting and board-level discussions, even though directors must follow trading rules and are restricted around major announcements. This trade also fits with recent buying activity at Abbott. Within the last 30 days, another insider, Philip P. Boudreau, purchased roughly $201,300 of shares on April 23, 2026. Two purchases close together—especially with Starks’ much larger buy—stand out against periods where insider activity is dominated by equity grants or other non-open-market acquisitions that don’t require insiders to commit capital.